FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667551> ?p ?o ?g. }

• W4385667551 endingPage "e506783a" @default.
• W4385667551 startingPage "e506783a" @default.
• W4385667551 abstract "Background: Bosutinib is a second-generation Tyrosine Kinase Inhibitor (TKI), approved for adults with Chronic Myeloid Leukemia (CML), and tested for the first time in children in this phase I/II trial, sponsored by Erasmus Medical Center and the Children’s Oncology Group, and funded by Pfizer Inc. The phase I arm established the recommended phase 2 dose (RP2D) in resistant/intolerant (R/I) pediatric patients at 400 mg/m2 QD (max 600 mg/day), based on safety and target exposure as defined in adults. Extrapolation from safety and PK data in R/I children and target exposure from adults established the RP2D for newly diagnosed (ND) patients at 300 mg/m2 QD (max 500 mg/day). Aims: We present updated safety and efficacy results of bosutinib in R/I pediatric patients with CML treated at the RP2D in the phase I and II portion of the study, as well as efficacy data in ND patients. Methods: R/I and ND patients (as per ELN2013 criteria), aged 1-18 years with chronic phase CML, without evidence for organ toxicities, were enrolled. Main exclusion criteria included known T315I or V299L BCR-ABL1 mutations, use of proton pump inhibitors and CYP3A inducers/inhibitors. Due to the rarity of CML in children, the sample size was not based on formal calculations: a total of 60 patients needed to be enrolled in this phase I/II combined study per regulatory authorities’ requirements. Results: Thirteen R/I patients received the RP2D of which 11 were in phase I. Median age was 15 (range: 6-17) years, sex M:F ratio 8:5. Twelve patients were resistant and 1 intolerant to prior therapy with 5 patients having received ≥2 previous TKIs. Seven were reported in Complete Cytogenetic Response (CCyR) at baseline including 2 with Major Molecular Response (MMR). Ten patients received the capped dose of 600 mg/day. Median follow-up was 11 (range 1-25) months. At the RP2D, one patient experienced a DLT in phase I (transaminase and bilirubin increase and rash). Gastrointestinal (GI) and skin toxicities were the most common; namely 12/13 (92%) with diarrhea, of which 2 (17%) were grade 3/4, and 8/13 (62%) with skin rash, of which 1 (13%) was grade 3/4. At time of dataset lock (February 14, 2023), 11/13 (84.6%) R/I patients achieved/maintained CCyR, and 7/13 (53.8%) MMR, as best response. One patient who achieved CCyR on treatment lost the response after 12 months, while all patients which entered the study with either CCyR or MMR maintained the response. Of the 5 patients not in CCyR at baseline, 4 (80%, 95%CI: 28-99%) achieved CCyR and 1 had no response data available (on treatment for <1 month). Of the 10 patients not in MMR at baseline, 5 (50%, 95%CI: 19-81%) achieved MMR on study (2 had no response data available, on treatment for <3 months). Median time to response was 3 months for CCyR and 8 months for MMR. Two patients permanently discontinued the drug due to toxicities (one rash, one persistent GI toxicity and fatigue), three due to insufficient response. In phase II, 24 ND patients were enrolled: sex M:F ratio 15:9, median age 13 (range: 5-17) years. The median follow-up was 14 (range: 0.9-31) months. Cumulative incidence of CCyR was 77% (47%-91%) and 88.3% (95%CI 55%-98%) at 6 and 12 months respectively, and for MMR it was 23% (95%CI 7%-46%) and 30% (95%CI 10%-54%). Three patients permanently discontinued bosutinib due to intolerance four due to unsatisfactory response with 17 still on treatment at time of dataset lock. Summary/Conclusion: Bosutinib at the RP2D was well-tolerated and its preliminary efficacy in R/I and ND pediatric patients seems comparable to that recorded in adult patients treated with the same drug and in line with other second generation TKIs. Keywords: Pediatric, Chronic myeloid leukemia, Clinical trial" @default.
• W4385667551 created "2023-08-09" @default.
• W4385667551 creator A5000382317 @default.
• W4385667551 creator A5000934222 @default.
• W4385667551 creator A5005516784 @default.
• W4385667551 creator A5010531755 @default.
• W4385667551 creator A5012000455 @default.
• W4385667551 creator A5013118432 @default.
• W4385667551 creator A5013804946 @default.
• W4385667551 creator A5017277128 @default.
• W4385667551 creator A5021059238 @default.
• W4385667551 creator A5022712318 @default.
• W4385667551 creator A5025366310 @default.
• W4385667551 creator A5028181038 @default.
• W4385667551 creator A5032647184 @default.
• W4385667551 creator A5035455886 @default.
• W4385667551 creator A5037565260 @default.
• W4385667551 creator A5038753379 @default.
• W4385667551 creator A5040968322 @default.
• W4385667551 creator A5042196764 @default.
• W4385667551 creator A5042296689 @default.
• W4385667551 creator A5044457816 @default.
• W4385667551 creator A5052857128 @default.
• W4385667551 creator A5053567227 @default.
• W4385667551 creator A5053691098 @default.
• W4385667551 creator A5054346760 @default.
• W4385667551 creator A5057118400 @default.
• W4385667551 creator A5062385452 @default.
• W4385667551 creator A5064497930 @default.
• W4385667551 creator A5066273967 @default.
• W4385667551 creator A5066587433 @default.
• W4385667551 creator A5068113825 @default.
• W4385667551 creator A5069036596 @default.
• W4385667551 creator A5070410235 @default.
• W4385667551 creator A5075183737 @default.
• W4385667551 creator A5075351116 @default.
• W4385667551 creator A5075519499 @default.
• W4385667551 creator A5086994519 @default.
• W4385667551 creator A5088976238 @default.
• W4385667551 creator A5092614099 @default.
• W4385667551 date "2023-08-01" @default.
• W4385667551 modified "2023-10-01" @default.
• W4385667551 title "P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA" @default.
• W4385667551 doi "https://doi.org/10.1097/01.hs9.0000969608.50678.3a" @default.
• W4385667551 hasPublicationYear "2023" @default.
• W4385667551 type Work @default.
• W4385667551 citedByCount "0" @default.
• W4385667551 crossrefType "journal-article" @default.
• W4385667551 hasAuthorship W4385667551A5000382317 @default.
• W4385667551 hasAuthorship W4385667551A5000934222 @default.
• W4385667551 hasAuthorship W4385667551A5005516784 @default.
• W4385667551 hasAuthorship W4385667551A5010531755 @default.
• W4385667551 hasAuthorship W4385667551A5012000455 @default.
• W4385667551 hasAuthorship W4385667551A5013118432 @default.
• W4385667551 hasAuthorship W4385667551A5013804946 @default.
• W4385667551 hasAuthorship W4385667551A5017277128 @default.
• W4385667551 hasAuthorship W4385667551A5021059238 @default.
• W4385667551 hasAuthorship W4385667551A5022712318 @default.
• W4385667551 hasAuthorship W4385667551A5025366310 @default.
• W4385667551 hasAuthorship W4385667551A5028181038 @default.
• W4385667551 hasAuthorship W4385667551A5032647184 @default.
• W4385667551 hasAuthorship W4385667551A5035455886 @default.
• W4385667551 hasAuthorship W4385667551A5037565260 @default.
• W4385667551 hasAuthorship W4385667551A5038753379 @default.
• W4385667551 hasAuthorship W4385667551A5040968322 @default.
• W4385667551 hasAuthorship W4385667551A5042196764 @default.
• W4385667551 hasAuthorship W4385667551A5042296689 @default.
• W4385667551 hasAuthorship W4385667551A5044457816 @default.
• W4385667551 hasAuthorship W4385667551A5052857128 @default.
• W4385667551 hasAuthorship W4385667551A5053567227 @default.
• W4385667551 hasAuthorship W4385667551A5053691098 @default.
• W4385667551 hasAuthorship W4385667551A5054346760 @default.
• W4385667551 hasAuthorship W4385667551A5057118400 @default.
• W4385667551 hasAuthorship W4385667551A5062385452 @default.
• W4385667551 hasAuthorship W4385667551A5064497930 @default.
• W4385667551 hasAuthorship W4385667551A5066273967 @default.
• W4385667551 hasAuthorship W4385667551A5066587433 @default.
• W4385667551 hasAuthorship W4385667551A5068113825 @default.
• W4385667551 hasAuthorship W4385667551A5069036596 @default.
• W4385667551 hasAuthorship W4385667551A5070410235 @default.
• W4385667551 hasAuthorship W4385667551A5075183737 @default.
• W4385667551 hasAuthorship W4385667551A5075351116 @default.
• W4385667551 hasAuthorship W4385667551A5075519499 @default.
• W4385667551 hasAuthorship W4385667551A5086994519 @default.
• W4385667551 hasAuthorship W4385667551A5088976238 @default.
• W4385667551 hasAuthorship W4385667551A5092614099 @default.
• W4385667551 hasBestOaLocation W43856675511 @default.
• W4385667551 hasConcept C126322002 @default.
• W4385667551 hasConcept C143998085 @default.
• W4385667551 hasConcept C187212893 @default.
• W4385667551 hasConcept C2777583451 @default.
• W4385667551 hasConcept C2778208673 @default.
• W4385667551 hasConcept C2778729363 @default.
• W4385667551 hasConcept C2779536868 @default.
• W4385667551 hasConcept C71924100 @default.
• W4385667551 hasConceptScore W4385667551C126322002 @default.
• W4385667551 hasConceptScore W4385667551C143998085 @default.
• W4385667551 hasConceptScore W4385667551C187212893 @default.

• next